202 related articles for article (PubMed ID: 21362449)
1. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration.
Wen Z; Yan Z; Hu K; Pang Z; Cheng X; Guo L; Zhang Q; Jiang X; Fang L; Lai R
J Control Release; 2011 Apr; 151(2):131-8. PubMed ID: 21362449
[TBL] [Abstract][Full Text] [Related]
2. Brain targeting and toxicity study of odorranalectin-conjugated nanoparticles following intranasal administration.
Wen Z; Yan Z; He R; Pang Z; Guo L; Qian Y; Jiang X; Fang L
Drug Deliv; 2011 Nov; 18(8):555-61. PubMed ID: 21812752
[TBL] [Abstract][Full Text] [Related]
3. A novel small Odorranalectin-bearing cubosomes: preparation, brain delivery and pharmacodynamic study on amyloid-β₂₅₋₃₅-treated rats following intranasal administration.
Wu H; Li J; Zhang Q; Yan X; Guo L; Gao X; Qiu M; Jiang X; Lai R; Chen H
Eur J Pharm Biopharm; 2012 Feb; 80(2):368-78. PubMed ID: 22061263
[TBL] [Abstract][Full Text] [Related]
4. Solanum tuberosum lectin-conjugated PLGA nanoparticles for nose-to-brain delivery: in vivo and in vitro evaluations.
Chen J; Zhang C; Liu Q; Shao X; Feng C; Shen Y; Zhang Q; Jiang X
J Drug Target; 2012 Feb; 20(2):174-84. PubMed ID: 21992548
[TBL] [Abstract][Full Text] [Related]
5. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration.
Gao X; Wu B; Zhang Q; Chen J; Zhu J; Zhang W; Rong Z; Chen H; Jiang X
J Control Release; 2007 Aug; 121(3):156-67. PubMed ID: 17628165
[TBL] [Abstract][Full Text] [Related]
6. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease.
Hu K; Shi Y; Jiang W; Han J; Huang S; Jiang X
Int J Pharm; 2011 Aug; 415(1-2):273-83. PubMed ID: 21651967
[TBL] [Abstract][Full Text] [Related]
7. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration.
Gao X; Tao W; Lu W; Zhang Q; Zhang Y; Jiang X; Fu S
Biomaterials; 2006 Jun; 27(18):3482-90. PubMed ID: 16510178
[TBL] [Abstract][Full Text] [Related]
8. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration.
Xia H; Gao X; Gu G; Liu Z; Zeng N; Hu Q; Song Q; Yao L; Pang Z; Jiang X; Chen J; Chen H
Biomaterials; 2011 Dec; 32(36):9888-98. PubMed ID: 21937105
[TBL] [Abstract][Full Text] [Related]
9. Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment.
Bi C; Wang A; Chu Y; Liu S; Mu H; Liu W; Wu Z; Sun K; Li Y
Int J Nanomedicine; 2016; 11():6547-6559. PubMed ID: 27994458
[TBL] [Abstract][Full Text] [Related]
10. Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease.
Zhang C; Chen J; Feng C; Shao X; Liu Q; Zhang Q; Pang Z; Jiang X
Int J Pharm; 2014 Jan; 461(1-2):192-202. PubMed ID: 24300213
[TBL] [Abstract][Full Text] [Related]
11. Odorranalectin modified PEG-PLGA/PEG-PBLG curcumin-loaded nanoparticle for intranasal administration.
Li X; Su J; Kamal Z; Guo P; Wu X; Lu L; Wu H; Qiu M
Drug Dev Ind Pharm; 2020 Jun; 46(6):899-909. PubMed ID: 32375569
[TBL] [Abstract][Full Text] [Related]
12. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration.
Liu Z; Jiang M; Kang T; Miao D; Gu G; Song Q; Yao L; Hu Q; Tu Y; Pang Z; Chen H; Jiang X; Gao X; Chen J
Biomaterials; 2013 May; 34(15):3870-81. PubMed ID: 23453061
[TBL] [Abstract][Full Text] [Related]
13. UEA I-bearing nanoparticles for brain delivery following intranasal administration.
Gao X; Chen J; Tao W; Zhu J; Zhang Q; Chen H; Jiang X
Int J Pharm; 2007 Aug; 340(1-2):207-15. PubMed ID: 17499948
[TBL] [Abstract][Full Text] [Related]
14. In vivo toxicity and immunogenicity of wheat germ agglutinin conjugated poly(ethylene glycol)-poly(lactic acid) nanoparticles for intranasal delivery to the brain.
Liu Q; Shao X; Chen J; Shen Y; Feng C; Gao X; Zhao Y; Li J; Zhang Q; Jiang X
Toxicol Appl Pharmacol; 2011 Feb; 251(1):79-84. PubMed ID: 21163285
[TBL] [Abstract][Full Text] [Related]
15. Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin.
Yin Y; Chen D; Qiao M; Lu Z; Hu H
J Control Release; 2006 Dec; 116(3):337-45. PubMed ID: 17097180
[TBL] [Abstract][Full Text] [Related]
16. Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review.
Kulkarni AD; Vanjari YH; Sancheti KH; Belgamwar VS; Surana SJ; Pardeshi CV
J Drug Target; 2015; 23(9):775-88. PubMed ID: 25758751
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle-mediated delivery of neurotoxin-II to the brain with intranasal administration: an effective strategy to improve antinociceptive activity of neurotoxin.
Ruan Y; Yao L; Zhang B; Zhang S; Guo J
Drug Dev Ind Pharm; 2012 Jan; 38(1):123-8. PubMed ID: 21721852
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of hyaluronic acid decorated PLGA nanoparticles for delivery of 5-fluorouracil.
Yadav AK; Agarwal A; Rai G; Mishra P; Jain S; Mishra AK; Agrawal H; Agrawal GP
Drug Deliv; 2010 Nov; 17(8):561-72. PubMed ID: 20738221
[TBL] [Abstract][Full Text] [Related]
19. Lactoferrin-modified rotigotine nanoparticles for enhanced nose-to-brain delivery: LESA-MS/MS-based drug biodistribution, pharmacodynamics, and neuroprotective effects.
Yan X; Xu L; Bi C; Duan D; Chu L; Yu X; Wu Z; Wang A; Sun K
Int J Nanomedicine; 2018; 13():273-281. PubMed ID: 29391788
[TBL] [Abstract][Full Text] [Related]
20. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model.
Md S; Khan RA; Mustafa G; Chuttani K; Baboota S; Sahni JK; Ali J
Eur J Pharm Sci; 2013 Feb; 48(3):393-405. PubMed ID: 23266466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
